Results 201 to 210 of about 589,499 (392)

Cholinergic System Changes in Dopa‐Unresponsive Freezing of Gait in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Freezing of gait (FoG) is a debilitating mobility disturbance that becomes increasingly resistant to dopaminergic pharmacotherapies with advancing Parkinson's disease (PD). The pathophysiology underlying the response of FoG to dopaminergic treatment is poorly understood.
Kelvin L. Chou, Prabesh Kanel, Miriam van Emde Boas, Stiven Roytman, Giulia Carli, Roger L. Albin, Nicolaas I. Bohnen   +6 more
wiley   +1 more source

Advances in the Therapeutic Use of Non-Ergot Dopamine Agonists in the Treatment of Motor and Non-Motor Symptoms of Parkinson's Disease. [PDF]

Curr Neuropharmacol, 2023
Jing XZ, Yang HJ, Taximaimaiti R, Wang XP.   +3 more
europepmc   +1 more source

Unsettling the Hegemony of Intention: Agonistic Image Generation [PDF]

arXiv
Current image generation paradigms prioritize actualizing user intention - "see what you intend" - but often neglect the sociopolitical dimensions of this process. However, it is increasingly evident that image generation is political, contributing to broader social struggles over visual meaning.
arxiv  

Pramipexole protective effect on rotenone induced neurotoxicity in mice [PDF]

, 2011
Introduction: Pramipexole is a new dopaminergic drug which has been approved for PD treatment. However, we tried to find a new capacity for this drug rather than symptomatic effect. Materials and Methods: A chronic
Abdelaziz A. Ghanem, Dina El-Tantawy, Hasan Abd-Elghaffar, Mohamed M. Salama, Sahar A. El-Dakroury, Sara El-Dosouky, Seham A. Gad-Elhak   +6 more
core   +1 more source

Dopamine agonists both stimulate and inhibit prolactin release in GH4ZR7 cells [PDF]

, 1999
Annisa Chang, Shin Sh
openalex   +1 more source

Cognitive and Psychiatric Adverse Effects of Foslevodopa/Foscarbidopa in Patients with Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Sacha Brohée, Emmanuel Roze, David Grabli, Hélène Letrillart, Lise Mantisi, Cendrine Foucard, Elodie Hainque, Florence Cormier, Aurélie Méneret, Fabien Hauw   +9 more
wiley   +1 more source

Cortical Effects of Dopamine Replacement Account for Clinical Response Variability in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Background Individual variability in clinical response to dopamine replacement therapy (DRT) is a key barrier to efficacious treatment for patients with Parkinson's disease (PD). A better understanding of the neurobiological sources of such interindividual differences is necessary to personalize DRT prescribing, inform future clinical ...
Alex I. Wiesman, Mikkel C. Vinding, Panagiota Tsitsi, Per Svenningsson, Josefine Waldthaler, Daniel Lundqvist   +5 more
wiley   +1 more source

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms. [PDF]

Front Endocrinol (Lausanne), 2021
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R, Auriemma RS.   +6 more
europepmc   +1 more source

A pseudopeptide that is a potent cholecystokinin agonist in the peripheral system is able to inhibit the dopamine-like effects of cholecystokinin in the striatum.

, 1988
Christiane Mendre, Meghan Rodriquez, Christiane Gueudet, MARIE‐FRANÇOISE LIGNON, Marie‐Christine Galas, Jeanine Laur, P. Worms, Jean Martínez   +7 more
openalex   +1 more source

Dopaminergic Regulation of Progesterone Receptors: Brain D5 Dopamine Receptors Mediate Induction of Lordosis by D1-Like Agonists in Rats [PDF]

, 1996
Ede Marie Apostolakis, János Garai, Charles A. Fox, C. Smith, Stanley J. Watson, James H. Clark, Bert W. O’Malley   +6 more
openalex   +1 more source